News Focus
News Focus
Followers 26
Posts 8986
Boards Moderated 0
Alias Born 12/11/2013

Re: None

Tuesday, 11/20/2018 6:07:11 PM

Tuesday, November 20, 2018 6:07:11 PM

Post# of 405224
Final CRO payment should have been negotiated and completed before the below PR.....

http://www.ipharminc.com/press-release/2018/6/29/innovation-pharmaceuticals-announces-database-lock-for-phase-2b-trial-of-oral-prurisol-for-psoriasis

Locking the database is a key step toward analyzing data from our randomized, placebo-controlled trial of Prurisol, one of the larger studies we’ve conducted to date,” commented Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “We are excited to have reached this milestone and will now move to process trial data and report topline study results. Psoriasis is a large market for which new treatments, particularly oral medications, are highly sought after by providers and patients.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y